Abstract
Introduction: With the development of the direct acting antivirals aganist hepatitis C virus (HCV), the treatment of HCV has showed significiant progress. However, hepatitis B virus (HBV) therapy is still a topic of discussion.
Objectives: Because of that approved agents for HBV have some disadvantages including indefinite therapy, drug resistance, adverse effects and persistence of covalently closed circular deoxyribonucleic acid (cccDNA), there is a need for new treatment targets and approaches for HBV. And, there are several trials about this subject. New treatment targets for HBV consist revers transcription, immunoregulation, cccDNA formation and regulation, maturation and secretion of infectious virions and subviral particules, viral receptor, entry and cytosolic transport, nucleocapsid assembly. Therapeutic vaccination and traditional Chinese medicine are the other options for novel agents for HBV treatment. We summarised new treatment targets and approaches for HBV. Conclusion: It is a certain fact that large-scale studies about all these molecules and approaches are required, in order to highlight the efficiency, drug interaction, safety and appropriate dose.Keywords: Hepatitis B virus, treatment, nucleos(t)id analogues, cccDNA, immunoregulators, viral entry, traditional Chinese medicine.
Graphical Abstract
Anti-Infective Agents
Title:New Treatment Targets and Approaches for Hepatitis B Virus
Volume: 15 Issue: 1
Author(s): Murat Afyon*Cumhur Artuk
Affiliation:
- GATA Haydarpasa Training Hospital, Primary Care and Examination, Family Health Center and the Naval Academy Clinic, Tuzla/Istanbul,Turkey
Keywords: Hepatitis B virus, treatment, nucleos(t)id analogues, cccDNA, immunoregulators, viral entry, traditional Chinese medicine.
Abstract: Introduction: With the development of the direct acting antivirals aganist hepatitis C virus (HCV), the treatment of HCV has showed significiant progress. However, hepatitis B virus (HBV) therapy is still a topic of discussion.
Objectives: Because of that approved agents for HBV have some disadvantages including indefinite therapy, drug resistance, adverse effects and persistence of covalently closed circular deoxyribonucleic acid (cccDNA), there is a need for new treatment targets and approaches for HBV. And, there are several trials about this subject. New treatment targets for HBV consist revers transcription, immunoregulation, cccDNA formation and regulation, maturation and secretion of infectious virions and subviral particules, viral receptor, entry and cytosolic transport, nucleocapsid assembly. Therapeutic vaccination and traditional Chinese medicine are the other options for novel agents for HBV treatment. We summarised new treatment targets and approaches for HBV. Conclusion: It is a certain fact that large-scale studies about all these molecules and approaches are required, in order to highlight the efficiency, drug interaction, safety and appropriate dose.Export Options
About this article
Cite this article as:
Afyon Murat*, Artuk Cumhur, New Treatment Targets and Approaches for Hepatitis B Virus, Anti-Infective Agents 2017; 15 (1) . https://dx.doi.org/10.2174/2211352514666161025113118
DOI https://dx.doi.org/10.2174/2211352514666161025113118 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Designing of Selective γ-Secretase Inhibitory Benzenesulfonamides through Comparative In Vitro and In Silico Analysis
Current Drug Discovery Technologies Inhibitory MHC Class I Receptors on Myeloid Cells
Current Immunology Reviews (Discontinued) CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry Lipopolysaccharide-Induced Chorioamnionitis Causes Acute Inflammatory Changes in the Ovine Central Nervous System
CNS & Neurological Disorders - Drug Targets ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential
Current Stem Cell Research & Therapy Is Autoimmunity a Component of Natural Immunity to HIV?
Current HIV Research Synthesis and in vitro Evaluation of the Anticancer Potential of New Aminoalkanol Derivatives of Xanthone
Anti-Cancer Agents in Medicinal Chemistry Hepatocyte Growth Factor (HGF) for a Cell-Signal-Based Therapy During Acute and Chronic Liver Diseases
Current Signal Transduction Therapy Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Bioactive Compound and Nanotechnology: A Novel Delivery Perspective for Diabetic Retinopathy
Current Bioactive Compounds The Role of Toll-Like Receptors and Type I Interferons in Host Responses to Bacteria
Current Immunology Reviews (Discontinued) Recent Patents on Oral Insulin Delivery
Recent Patents on Drug Delivery & Formulation Activation and Regulation of Toll-like Receptor 9: CpGs and Beyond
Mini-Reviews in Medicinal Chemistry Application of Decoy Oligonucleotides as Novel Therapeutic Strategy: A Contemporary Overview
Current Drug Discovery Technologies Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry